David Happel - President & CEO, Director at Sagimet Biosciences Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
President & CEO, Director
Issuer Symbol
SGMT on Nasdaq
All Insider Reports
All Insider Reports

David Happel - trading volume in the past year for Sagimet Biosciences Inc.

Holdings reported by David Happel for Sagimet Biosciences Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Series A Common Stock 805,621 $4,720,939 $5.86 19 Feb 2026 Direct
Stock Option (Right to Buy) 256,000 19 Feb 2026 Direct Series A Common Stock

Transactions reported by David Happel for Sagimet Biosciences Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.